SCHEMBL30765836

SCHEMBL30765836

CC(C)(C)OC(=O)Cn1c(N2CC(F)C2)ncc(NCc2ccc3oc4ccccc4c3c2)c1=O

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HCRTR1 O43613 15/20 0.36
HCRTR2 O43614 15/20 0.36
CYP3A4 P08684 4/20 0.35
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
JAK3 P52333 1/20 0.34
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765939 0.97 LMNA (0.35) KDM4EALDH1A1LMNAMEN1MAPT
SCHEMBL30765778 0.88 LMNA (0.37) KDM4EALDH1A1LMNAMEN1MAPT
SCHEMBL30765777 0.83 HCRTR1 (0.40) KDM4EALDH1A1LMNAMEN1MAPT
SCHEMBL30765705 0.83 ALDH1A1 (0.38) KDM4EALDH1A1LMNAMEN1MAPT
SCHEMBL30765784 0.79 NPSR1 (0.35) KDM4EALDH1A1LMNAMEN1MAPT
SCHEMBL30765948 0.78 LMNA (0.39) LMNA
SCHEMBL30765535 0.78 F2 (0.34) ALDH1A1MAPTKMT2A
SCHEMBL30766002 0.76 USP2 (0.37) KDM4EALDH1A1LMNAMAPTKMT2A
SCHEMBL30765442 0.76 ELANE (0.38) KDM4EALDH1A1LMNAMEN1MAPT
SCHEMBL30765500 0.72 ALDH1A1 (0.41) KDM4EALDH1A1MAPTSMN1; SMN2JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed